Metsera, Inc.
MTSR
Kedudukan dalam Saham
#2575
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Harga Saham
$70.50
Disegerakkan terakhir: 2025-11-14
Modal Pasaran
$7.33B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
33.60%
Negara
US
Perdagangan Metsera, Inc. (MTSR)
Kategori
Healthcare
Nisbah P/S bagi Metsera, Inc. (MTSR)
Nisbah P/S pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Metsera, Inc., nisbah P/S semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/S syarikat ialah 0.
Sejarah nisbah P/S untuk Metsera, Inc. dari 2026 hingga 2026
Nisbah P/S pada akhir setiap tahun
| Tahun | Nisbah P/S | Ubah |
|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | ||
Nisbah P/S untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/S | Perbezaan Nisbah P/S | Negara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
